CMN-005 is under clinical development by CoImmune and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According to GlobalData, Phase II drugs for Splenic Marginal Zone B-Cell Lymphoma have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CMN-005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CMN-005 overview

CMN-005 is under development for the treatment of relapsed and refractory B-cell acute lymphocytic leukemia, chronic lymphocytic leukemia (CLL) and b-cell non-Hodgkin lymphoma, follicular lymphoma, marginal zone lymphoma nodal; extra-nodal; or splenic, diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, mantle cell lymphoma, post bone marrow transplantation. It constitutes of Chimeric Antigen Receptor (CAR) modified Cytokine Induced Killer (C.I.K.) cells. It acts by targeting the cancer cells which express CD19 antigen. The cell therapy is developed based on C.I.K. CAR technology that utilizes SB100X transposase, a component of the non-viral, Sleeping Beauty transposon-based gene transfer system. It is administered through intravenous route.

See Also:

CoImmune overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CoImmune is a biopharmaceutical company that carries out the development and manufacture of immunotherapies to treat cancer, inflammatory and autoimmune diseases. Its clinical products pipeline includes CARCIK-CD19 (CMN-005), CAR-CIK (CMN-006), CAR-CIK solid tumors, and CMN-001. The comnpany’s products are used in the treatment of acute lymphoblastic leukemia, non-hodgkin’s lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, and metastatic renal cell carcinoma, among others. It also carries out the research and development activities through its cell therapy technology platforms which include allogeneic cytokine-induced killer (CIK) and autologous RNA-loaded dendritic cells. CoImmune is headquartered in Durham, North Carolina, the US.

For a complete picture of CMN-005’s drug-specific PTSR and LoA scores, buy the report here.